Compare CVV & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | CTXR |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 18.9M |
| IPO Year | 2007 | 2010 |
| Metric | CVV | CTXR |
|---|---|---|
| Price | $5.84 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 182.2K | ★ 742.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.86 | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,128,639.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 96.27 | N/A |
| 52 Week Low | $2.75 | $0.48 |
| 52 Week High | $8.46 | $2.38 |
| Indicator | CVV | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 41.31 |
| Support Level | $3.25 | $0.48 |
| Resistance Level | $6.25 | $0.99 |
| Average True Range (ATR) | 0.67 | 0.07 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 44.34 | 40.78 |
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts, MesoScribe. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment. Company operates in USA, North America, Europe, Middle East and Africa, and Asia-Pacific.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.